Abstract Number: 1801 • 2012 ACR/ARHP Annual Meeting
Biological Roles of C5orf30 in Rheumatoid Arthritis
Background/Purpose: A recent genome wide association study identified the variant rs26232 in the first exon of an uncharacterized gene C5orf30. In addition, this variant is…Abstract Number: 1802 • 2012 ACR/ARHP Annual Meeting
Interleukin-29 Modulates Proinflammatory Cytokine Production in Synovial Inflammation of Rheumatoid Arthritis
Background/Purpose: The immunoregulatory function of interleukin (IL)-29 has recently been recognized. However, little is known about the involvement of IL-29 in the pathogenesis of rheumatoid…Abstract Number: 1803 • 2012 ACR/ARHP Annual Meeting
Chemokine-Like Receptor 1 (CMKLR1), a G Protein Coupled Receptor Expressed On Proinflammatory Monocytes in Arthritis, Is Negatively Regulated by GRK3
Background/Purpose: Chemokine-like receptor 1 (CMKLR1) is a G protein coupled receptor (GPCR) expressed by inflammatory monocytes that are pathogenic in human diseases such as psoriasis…Abstract Number: 1804 • 2012 ACR/ARHP Annual Meeting
TNF-Like Protein 1A/Death Receptor 3 Pathway Regulates Osteoclastogenesis and Is Associated with Erosive Disease in Rheumatoid Arthritis
Background/Purpose: Bone erosion is a characteristic feature of inflammatory arthritides, such as rheumatoid arthritis (RA). Death Receptor 3 (DR3) and its only known ligand TNF-like…Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting
The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor
Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…Abstract Number: 1806 • 2012 ACR/ARHP Annual Meeting
A Novel Angiopoetin2/TEK Tyrosine Kinase Receptor Mediated Effect On Leukocyte Cell Influx and Oxidative Damage in Inflammatory Arthritis
Background/Purpose: The Angiopoietin2 (Ang2)/TEK Tyrosine Kinase Receptor (Tie2) signalling pathway acts synergistically with VEGF/flk as critical regulators of new vessel growth, morphology and stability possibly…Abstract Number: 1808 • 2012 ACR/ARHP Annual Meeting
Immune Activating Effects of Co-Stimulation of TLR Agonists and Cytokines On Primary and Immortalized Keratinocytes From a Patient with a CARD14 Mediated Pustular Psoriasis (CAMPS) and Healthy Controls
Background/Purpose: Through producing inflammatory cytokines and chemokines, keratinocytes play an important role along with hematopoietic cells in mediating an inflammatory response in psoriasis and other…Abstract Number: 1809 • 2012 ACR/ARHP Annual Meeting
Serum IFNα Activity in Systemic Lupus Erythematosus Drops in Response to Immunosuppressive Therapy Only When There Is Concurrent Clinical Response
Background/Purpose: The type I interferon (IFN-I) signature, describing expression in PBMC of a large set of gene transcripts induced by IFN-I, and increased serum IFNα…Abstract Number: 1810 • 2012 ACR/ARHP Annual Meeting
Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL17A
Background/Purpose: : IL17A has been demonstrated to be a key pro-inflammatory cytokine in human rheumatoid arthritis and in several rodent models of arthritis. Synthetic macrocycles…Abstract Number: 1811 • 2012 ACR/ARHP Annual Meeting
On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis
Background/Purpose: Presence of a type I interferon (IFN) signature has been described for several autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).…Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…Abstract Number: 1813 • 2012 ACR/ARHP Annual Meeting
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Background/Purpose: Gout outcome studies have used administrative and claims databases. It is unknown whether administrative-derived data are accurate for gout-related utilization. The goal of the…Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…Abstract Number: 1815 • 2012 ACR/ARHP Annual Meeting
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Background/Purpose: Management of gout in the hospital setting has been poor. This study aimed to describe patient characteristics and the treatment patterns of acute gout…Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…
ACR Meeting Abstracts